Related references
Note: Only part of the references are listed.Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy
Yukina Sato et al.
ANTICANCER RESEARCH (2021)
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting
Axel S. Merseburger et al.
FRONTIERS IN ONCOLOGY (2021)
Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy
Hiroaki Iwamoto et al.
IN VIVO (2021)
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignanciesbendamustine and G-CSF support
Claudio Cerchione et al.
SUPPORTIVE CARE IN CANCER (2019)
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR
Thomas Fietz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Risk of pulmonary toxicity of bleomycin and filgrastim
Magali Laprise-Lachance et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor
Hiroaki Iwamoto et al.
IN VIVO (2018)
Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors
Yuki Maruyama et al.
MEDICAL ONCOLOGY (2018)
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Jie Xie et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
Claudio Cerchione et al.
SUPPORTIVE CARE IN CANCER (2017)
Myeloid Growth Factors, Version 2.2017 Clinical Practice Guidelines in Oncology
Jeffrey Crawford et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
Matti Aapro et al.
SUPPORTIVE CARE IN CANCER (2017)
Differential Sensitivity of Lipegfilgrastim and Pegfilgrastim to Neutrophil Elastase Correlates With Differences in Clinical Pharmacokinetic Profile
Afsaneh Abdolzade-Bavil et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Derek Weycker et al.
SUPPORTIVE CARE IN CANCER (2016)
A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma
Kohmei Kubo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
Yanli Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim
Bing-Bing Yang et al.
CLINICAL PHARMACOKINETICS (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
J. Crawford et al.
ANNALS OF ONCOLOGY (2010)
Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature
R. Veerappan et al.
BONE MARROW TRANSPLANTATION (2007)
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
JM O'Sullivan et al.
ANNALS OF ONCOLOGY (2003)
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
MD Green et al.
ANNALS OF ONCOLOGY (2003)
Share Paper
